Showing results (311-320 of 341) with videos related to

Sort By:
Pageof 35
Hepatology International|September 7, 2022
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohortYao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, et al.
Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Open Forum Infectious Diseases|December 30, 2020
Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|May 24, 2025
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus RegistryPing-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, et al.
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Pageof 35